Much to the disbelief of many, it has finally happened. FSD Pharma (CSE: HUGE) (NASDAQ: HUGE) has announced this morning that its subordinate voting shares will begin trading on the Nasdaq this week, with trading commencing January 9, 2020. The listing follows the preliminary approval announced by the firm on December 16, 2019.
Subordinate voting shares that trade on the Nasdaq will do so under the same ticker in which it currently trades on Canadian markets, “HUGE”. The firm has announced that it will continue to list its shares on the Canadian market even with the American listing. No intention to uplist from the Canadian Securities Exchange has been announced at this time by the firm.
I also want to extend my gratitude to the members of the Board of Directors of FSD Pharma, and especially to the founders of the Company, for their vision and for giving me an opportunity to lead the FSD Pharma team to achieve this strategic advantage. It is exciting to realize that once we begin trading on NASDAQ, we will be included in a select group of 12 Canadian-domiciled cannabis companies trading on either the NYSE or NASDAQ, and the first company in the history of the Canadian Securities Exchange (CSE) to be dual-listed on a major U.S. exchange.
Raza Bokhari, MD, Executive Co-Chairman and CEO.
Shares are to commence trading at market open on Thursday, January 9, 2020.
FSD Pharma last traded at $7.40 on the Canadian Securities Exchange.
Information for this briefing was found via Sedar, and FSD Pharma. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
